|Bid||6.86 x 1400|
|Ask||6.87 x 1800|
|Day's range||6.57 - 6.91|
|52-week range||4.68 - 19.22|
|Beta (5Y monthly)||1.00|
|PE ratio (TTM)||N/A|
|Earnings date||13 Apr 2022 - 18 Apr 2022|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||14 Oct 1999|
|1y target est||3.00|
Why Rite Aid's (NYSE: RAD) stock pop and raised guidance still aren't enough to get him interested in buying shares. Additionally, with shares down nearly 70% over the past year, is Zoom Video Communications (NASDAQ: ZM) a screaming buy or past its prime? To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center.
Yahoo Finance Live anchors discuss third-quarter earnings for Walgreens.
PHILADELPHIA, June 30, 2022--Elixir, a wholly owned subsidiary of Rite Aid (NYSE: RAD), announced the launch of a specialty generic medication enhancement to its managed copay solutions effective June 1, 2022. The enhancement allows members to receive generic versions of certain specialty medications at a $0 copay and has the potential to provide an average savings of up to $40,000 annually.